---

CEO and Founder, Sonoma Bio

It took Sonoma Bio CEO and founder Jeff Bluestone 12 years to engineer a process that allowed regulatory T cells (Tregs) to propagate – a feat that doesn’t even begin to cover the complex nature of Treg therapies. Under Bluestone’s leadership, Sonoma Bio has grown to more than 100 employees, broken ground on a state-of-the-art Treg R&D and manufacturing facility, entered the clinic with its lead Treg therapy for rheumatoid arthritis, and forged a novel 50/50 partnership with Regeneron to discover, develop, and commercialize Treg therapies for irritable bowel disease.

Beyond Sonoma Bio, Jeff has made storied contributions to the immunology field at large over his 40+ year career. He’s published more than 500 papers on T-cell activation and immune tolerance and was instrumental in developing teplizumab, a transformative medicine recently FDA-approved to delay the onset of Type 1 diabetes. 

“Throughout my career, I have lived by the mantra: ‘do kick-ass science, collaborate like hell, and make a difference.’ In this field, we’re working to change the whole paradigm of how to treat devastating autoimmune diseases.”